| Carbaprostacyclin, a PPARdelta agonist, ameliorates excess lipid accumulation in diabetic rat placentas. | |
| | |
MedLine Citation:
|
PMID: 20338185 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Maternal diabetes impairs placental development and metabolism. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors relevant in metabolic homeostasis. We investigated the concentrations of PPARdelta and its endogenous agonist prostacyclin (PGI2), as well as the effects of carbaprostacylin (cPGI(2,) a PPARdelta agonist) on lipid metabolism in placentas from control and streptozotocin-induced diabetic rats on day 13.5 of gestation. MAIN METHODS: The placentas were explanted to evaluate PPARdelta expression and PGI2 concentrations, and cultured with cPGI2 for further analysis of lipid metabolism (concentrations and (14)C-acetate derived synthesis of triglycerides, cholesteryl esters, phospholipids, cholesterol and free fatty acids; release of glycerol and lipid peroxidation). KEY FINDINGS: Reduced PGI2 concentrations were found in the placentas from diabetic rats when compared to controls. cPGI2 additions reduced the concentrations and synthesis of several lipid species, increased lipid catabolism and reduced lipid peroxidation in the placenta. These effects were more marked in diabetic tissues, which presented alterations in the lipid metabolic parameters evaluated. cPGI2 additions increased placental PPARdelta and acyl-CoA oxidase expression, which are changes possibly involved in the catabolic effects observed. SIGNIFICANCE: The present study reveals the capability of cPGI2 to regulate placental lipid metabolism and PPARdelta expression, and suggests that preserving appropriate PGI2 concentrations in the placenta may help to metabolize maternal derived lipid overload in diabetic gestations. |
| | |
Authors:
|
Melisa Kurtz; Evangelina Capobianco; Nora Mart?nez; Jimena Fern?ndez; Romina Higa; Ver?nica White; Alicia Jawerbaum |
Related Documents
:
|
1783885 - Absence of pregnancy-induced alterations in tissue insulin sensitivity in the offspring... 20685545 - Pregestational diabetes. 2134665 - Elevation of immunoreactive platelet prostaglandin e and plasma prostaglandin f2 alpha ... 11903395 - Normalization of pregnancy outcome in pregestational diabetes through functional insuli... 15025175 - Synthesis and antifungal properties of compounds which target the alpha-aminoadipate pa... 3345905 - A developmental-psychodynamic model for diabetic control. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-03-22 |
Journal Detail:
|
Title: Life sciences Volume: 86 ISSN: 1879-0631 ISO Abbreviation: Life Sci. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-11 Completed Date: 2010-05-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375521 Medline TA: Life Sci Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 781-90 Citation Subset: IM |
Affiliation:
|
Laboratory of Reproduction and Metabolism, CEFYBO-CONICET, School of Medicine, University of Buenos Aires, Paraguay Buenos Aires, Argentina. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acyl-CoA Oxidase
/
metabolism Animals Diabetes Mellitus, Experimental / complications, drug therapy Epoprostenol / analogs & derivatives*, analysis, pharmacology Female Glycerol / analysis Lipid Metabolism / drug effects Lipid Peroxidation / drug effects Lipids / analysis* PPAR delta / agonists*, analysis Placenta / chemistry, drug effects* Placenta Diseases / drug therapy, etiology Pregnancy Pregnancy in Diabetics / drug therapy*, metabolism Rats Rats, Wistar |
| Chemical | |
Reg. No./Substance:
|
0/Lipids; 0/PPAR delta; 0/carbaprostacyclin; 35121-78-9/Epoprostenol; 56-81-5/Glycerol; EC 1.3.3.6/Acyl-CoA Oxidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Magnesium deprivation inhibits a MEK-ERK cascade and cell proliferation in renal epithelial Madin-Da...
Next Document: Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity.